Elanco Animal Health Incorporated
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-71.5% vs price
Base Case (Median)
-42.3% vs price
Bull Case (75th pct.)
-38.8% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-0.15 | -100.6% | High (40%) |
| EV/EBITDA | $13.62 | -42.3% | Medium (20%) |
| EV/FCF | $15.27 | -35.3% | Medium (20%) |
Based on 3 out of 8 methods, ELAN appears overvalued at the current price of $23.61. The base case fair value of $13.62 implies 42.3% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.